Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease

Drug Metabolism and Disposition

Volumn 39, Issue 10, 2011, Pages 1954-1960

  Lake, April D ^a   Novak, Petr ^a,c   Fisher, Craig D ^a   Jackson, Jonathan P ^b   Hardwick, Rhiannon N ^a   Billheimer, D Dean ^a   Klimecki, Walter T ^a   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b CellzDirect Inc   (United States)

^c INSTITUTE OF PLANT MOLECULAR BIOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; MESSENGER RNA;

AGE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA MICROARRAY; DOWN REGULATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG UPTAKE; FATTY LIVER; GENDER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; NONALCOHOLIC FATTY LIVER; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL;

ABSORPTION; BIOLOGICAL TRANSPORT; DISEASE PROGRESSION; DOWN-REGULATION; FATTY LIVER; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIVER; MICROARRAY ANALYSIS; PHARMACEUTICAL PREPARATIONS; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 80053162318     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040592     Document Type: Article

References (38)

1. Aleksunes LM, Slitt AM, Cherrington NJ, Thibodeau MS, Klaassen CD, and Manautou JE (2005) Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci 83:44-52. (Pubitemid 40123329)
2. Aleksunes LM, Scheffer GL, Jakowski AB, Pruimboom-Brees IM, and Manautou JE (2006) Coordinated expression of multidrug resistance-associated proteins (Mrps) in mouse liver during toxicant-induced injury. Toxicol Sci 89:370-379. (Pubitemid 43125995)
3. Ali R, and Cusi K (2009) New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).Ann Med 41:265-278.
4. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, and Zein NN (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972-1978.
5. Baranova A, Schlauch K, Elariny H, Jarrar M, Bennett C, Nugent C, Gowder SJ, Younoszai Z, Collantes R, Chandhoke V, et al. (2007) Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obesity Surgery 17:1111-1118. (Pubitemid 350042936)
6. Baranova A, Schlauch K, Gowder S, Collantes R, Chandhoke V, and Younossi ZM (2005) Microarray technology in the study of obesity and non-alcoholic fatty liver disease. Liver Int 25:1091-1096. (Pubitemid 41782550)
7. Bellentani S, Scaglioni F, Marino M, and Bedogni G (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28:155-161.
8. Benjamini Y and Hochberg Y (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B Method 57:289-300.
9. Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, et al. (2010) Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 5.
10. Day CP (2002) Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16:663-678.
11. Day CP and James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114:842-845.
12. Wilfred de Alwis NM and Day CP (2008) Genes and nonalcoholic fatty liver disease. Curr Diab Rep 8:156-163.
13. Eloranta JJ and Meier PJ (2005) Coordinate transcriptional regulation of transport and metabolism, in Methods in Enzymology Phase II Conjugation Enzymes and Transport Systems, pp 511-530, Academic Press, San Diego, CA. (Pubitemid 43052437)
14. Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, and Cherrington NJ (2008) Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol 82:959-964.
15. Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, and Cherrington NJ (2009a) Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. European Journal of Pharmacology 613:119-127.
16. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, and Cherrington NJ (2009c) Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37:2087-2094.
17. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, et al. (2008) Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 294:G1281-G1287.
18. Guengerich FP (2008) Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70-83.
19. Hardwick RN, Fisher CD, Canet MJ, Lake AD, and Cherrington NJ (2010) Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 38:2293-2301.
20. Kleiner DE, Brunt EM, Van Natta ML, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Yeh M, et al. (2003) Design and validation of a histologic scoring system for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepatology 38:1313-1321. (Pubitemid 40770284)
21. Köhle C and Bock KW (2007) Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem Pharmacol 73:1853-1862. (Pubitemid 46677898)
22. Köhle C and Bock KW (2009) Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 77:689-699.
23. Lazarou J, Pomeranz BH, and Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205. (Pubitemid 28193431)
24. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, and Cherrington NJ (2007a) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 35:1970-1978. (Pubitemid 47481594)
25. Lickteig AJ, Slitt AL, Arkan MC, Karin M, and Cherrington NJ (2007b) Differential regulation of hepatic transporters in the absence of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and nuclear factor-kappaB in two models of cholestasis. Drug Metab Dispos 35:402-409. (Pubitemid 46333903)
26. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta F, and Spanish Collaborative Study Group on Therapeutic Management of Liver Diseases (2003) Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol 59:71-76.
27. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, and Kliewer SA (2002) Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638-646. (Pubitemid 36329382)
28. Morgan ET (2001) Regulation of cytochrome P450 by inflammatory mediators: Why and how? Drug Metab Dispos 29:207-212.
29. Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, and Maurel P (2008) The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 48:1-32. (Pubitemid 351738147)
30. Pessayre D, Fromenty B, and Mansouri A (2004) Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 16:1095-1105. (Pubitemid 39488778)
31. Portincasa P, Grattagliano I, Palmieri VO, and Palasciano G (2006) Current pharmacological treatment of nonalcoholic fatty liver. Curr Med Chem 13:2889-2900. (Pubitemid 44509714)
32. Renton KW (2005) Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 1:629-640.
33. Rombouts K and Marra F (2010) Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis. Dig Dis 28:229-235.
34. Rubio A, Guruceaga E, Vázquez-Chantada M, Sandoval J, Martínez-Cruz LA, Segura V, Sevilla JL, Podhorski A, Corrales FJ, Torres L, et al. (2007) Identification of a gene-pathway associated with non-alcoholic steatohepatitis. J Hepatol 46:708-718. (Pubitemid 46431167)
35. Smyth GK (2011) Bioinformatics and computational biology solutions using R and bioconductor, in Limma: Linear Models for Microarray Data (Gentleman R, Carey V, Dudoit R, and Irizarry W eds) pp 397-420, Springer, New York.
36. Szakács G, Váradi A, Ozvegy-Laczka C, and Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13:379-393.
37. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, et al. (2005a) A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42:665-674. (Pubitemid 41233660)
38. Younossi ZM, Gorreta F, Ong JP, Schlauch K, Del Giacco L, Elariny H, Van Meter A, Younoszai A, Goodman Z, Baranova A, et al. (2005b) Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int 25:760-771. (Pubitemid 41038658)